How Bioz Came to Be: The Benefits of AI-Powered Product Recommendations From a Researcher's Perspective
PALO ALTO, CALIFORNIA / ACCESS Newswire / January 27, 2025 / Bioz, Inc., a pioneer in AI-driven tools for scientific discovery, is transforming the way scientists discover and evaluate scientific products through its innovative Bioz Badges and Content Hub. These AI-driven product endorsements provide researchers with evidence-based recommendations, helping them identify the most trusted and frequently cited tools and reagents from a vast and often overwhelming selection.Scientific Discovery
The idea for Bioz originated from a personal challenge faced by Dr. Karin Lachmi, Chief Revenue Officer and Co-Founder of Bioz, during her time as a researcher. 'As a researcher myself, I often found it difficult to navigate the sea of products available on the market. Selecting reliable tools that would actually help my work was always a time-consuming and uncertain process,' Lachmi explains. 'That's when I realized there needed to be a smarter way - an AI-powered platform that could provide transparency, helping researchers make confident decisions based on data-driven insights.'
Bioz addresses this problem by offering a simple yet powerful way for researchers to assess the credibility of products. By leveraging Bioz's proprietary AI engine, which analyzes tens of millions of published research articles, clinical data, supplementary data, patents, and Ph.D. theses, Bioz Badges indicate which products are the most cited, trusted, and effective within specific scientific disciplines. This makes it easier for researchers to identify top-performing products without having to manually track down citation data. The badges offer immediate recognition of a product's quality, helping scientists save time and focus more on their research. With Bioz Badges, researchers can be confident that the products they choose have been validated by the scientific community, offering the highest levels of efficacy and reliability. Bioz also ensures that the latest, most innovative products are always highlighted, enabling researchers to stay at the forefront of scientific advancements. As a former researcher herself, Dr. Lachmi understands how critical it is to rely on trusted tools, and Bioz Badges were designed to make that process as straightforward and reliable as possible.
About Bioz
Bioz is the world's most advanced AI search engine for scientific research, offering evidence-based product ratings and recommendations to guide scientists toward the most validated products for their discoveries. Bioz's solutions for suppliers include Bioz Badges and Content Hubs, web-based widgets that enhance user engagement and increase sales conversion.
SOURCE: Bioz, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
an hour ago
- Indianapolis Star
Arrive AI Celebrates Nasdaq Debut by Ringing Opening Bell with Early Supporters, Pioneering the Future of Autonomous Delivery
INDIANAPOLIS, INDIANA / ACCESS Newswire Arrive AI (NASDAQ:ARAI) – a pioneering autonomous delivery network anchored by Arrive Points™ – is set to mark a pivotal moment in its journey by ringing Nasdaq's opening bell on July 3, 2025. More than 300 of the company's foundational investors, alongside team members, will join the celebration, highlighting the incredible support that fueled Arrive AI's ascent to the public market. 'This isn't just about ringing a bell; it's a testament to the vision and unwavering belief of our early investors who stood with us every step of the way,' said Arrive CEO Dan O'Toole. 'This landmark achievement is for everyone who joined our journey and made this moment possible. We are the real 'we the people' story!' Arrive AI officially began publicly trading on May 15, 2025. The company is rapidly transforming the autonomous delivery landscape with its Arrive Points, intelligent, networked smart mailboxes that serve as universal access points for both traditional and autonomous deliveries. This proprietary network offers an ever-growing suite of services, ranging from real-time data tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. The system seamlessly integrates with smart home devices such as doorbells, lighting and security systems, to streamline and secure the entire last-mile delivery experience. O'Toole's journey from designing the prototype Arrive Point on a napkin to ringing the Nasdaq bell began in 2014 when he sought U.S. Patent Office protection for his smart mailbox design. In doing so, he edged out Amazon by four days and other industry leaders by weeks. He secured that foundational patent in 2017 and has continued to refine the product and has also developed an AI-driven network and platform. Arrive AI now holds eight patents for its proprietary technology. Six additional patents are pending. Arrive AI has a total of 58 patents pending for its ALM solution filed across 22 countries and has secured several trademarks. See details at The latest patent highlights the Arrive Points' cutting-edge capabilities, including: Climate control: Ensuring the integrity of sensitive deliveries, Battery charging and exchange station: Supporting the evolving needs of autonomous vehicles, Advanced safety features: A collector for identifying explosive materials and anthrax, and ultraviolet and ozone applicators to eradicate disease, viruses and harmful materials, and Comprehensive monitoring: Weather monitoring; vehicle and package tracking; facial recognition camera and software for both humans and pets; local two-way speakers; and integrated flood light and strobe LED lighting. Arrive AI is actively collaborating with leaders in the healthcare industry where efficiency, accuracy and security are paramount for deliveries. O'Toole emphasizes the platform's vast potential for data tracking and other services, solidifying its position as a universal access point for the entire autonomous logistics industry. -30- About Arrive AI: Arrive AI's patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at Media contact: Cheryl Reed at media@ Investor Relations Contact: Alliance Advisors IR at Cautionary Note Regarding Forward Looking Statements This news release and statements of Arrive AI's management in connection with this news release or related events contain or may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as 'expects', 'anticipates', 'intends', 'plans', 'believes', 'potential', 'will', 'should', 'could', 'would' ,'optimistic' or 'may' and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI's public filings for more complete information, including the risk factors that may affect future results, which are available for review at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
Business Wire
an hour ago
- Business Wire
Ancora Heart Inc. Reaches First Enrollment Milestone in CORCINCH-HF Heart Failure Pivotal Trial
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that it has reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch ® Transcatheter Left Ventricular Restoration System in patients with heart failure with reduced ejection fraction (HFrEF). Six-month follow-up data on these 250 patients will support the company's Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA). 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle. Reaching this milestone is an incredible accomplishment in heart failure research." - Jeff Closs, president and CEO, Ancora Heart Share The AccuCinch System is an investigational device designed to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. Results from early clinical studies were presented at the 2023 Technology and Heart Failure Therapeutics conference and simultaneously published in the Journal of Cardiac Failure. The AccuCinch System was granted Breakthrough Device Designation from the FDA in 2022. 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle,' said Jeff Closs, president and CEO of Ancora Heart. 'Reaching this milestone is an incredible accomplishment in heart failure research and a model example of collaboration across heart failure and structural heart care teams at participating CORCINCH-HF clinical trial sites. We'd like to thank study investigators for their commitment to innovation and partnership, and we look forward to building on this momentum as we work toward reaching our full enrollment target of 400 patients.' The CORCINCH-HF study is evaluating the safety and effectiveness of the AccuCinch System in patients who have symptomatic HF with reduced ejection fraction. An estimated 6.7 million adults in the U.S. live with heart failure, and about half have HFrEF. 1,2 'Despite advances in guideline-directed medical therapy, many patients with heart failure continue to experience debilitating symptoms,' said Ulrich Jorde, MD, global co-principal investigator of the CORCINCH-HF Study, professor of medicine, Albert Einstein College of Medicine, and section head of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Montefiore Health System in New York. 'Reaching this milestone in the CORCINCH-HF study is a significant step toward determining whether this treatment option may improve the length and quality of their lives.' 'AccuCinch is a device-based therapy aimed at reverse remodeling of the enlarged left ventricle,' said Mark Reisman, MD*, global co-principal investigator of the CORCINCH-HF Study, director of structural heart disease at NewYork-Presbyterian/Weill Cornell Medical Center and co-director of structural heart disease for NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital, who was recruited to Weill Cornell Medicine as a professor of medicine. 'This trial is designed to evaluate the safety of the device and procedure and whether we can improve heart structure and function and thereby help patients feel better, avoid hospitalizations and live longer.' About Heart Failure An estimated 6.7 million adults in the U.S. live with heart failure, a condition in which the heart's muscles weaken and lose their ability to pump enough oxygen-rich blood to the body. 1,2 Heart failure patients suffer from debilitating symptoms, including persistent exhaustion, trouble breathing and confusion, as well as frequent hospitalizations. About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. Up to 50% of people who develop heart failure die within five years of diagnosis. 3 About the AccuCinch ® Transcatheter Left Ventricular Restoration System The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure patients. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant. During the minimally invasive AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. The AccuCinch System is under clinical evaluation to determine its potential benefits related to patient symptoms, quality of life and life expectancy. About the CORCINCH-HF Study The CORCINCH-HF Study (NCT04331769) is a prospective, randomized, open-label, multicenter, international, clinical safety and effectiveness investigation of the AccuCinch Transcatheter Left Ventricular Restoration System, which is designed to enroll 400 patients at centers worldwide. The study has a unique design allowing initial analysis of safety and clinical effectiveness for PMA submission after the first 250 patients have reached six months of follow-up, and then a second analysis after the entire cohort has reached 12 months of follow-up. About Ancora Heart, Inc. Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company's lead product is the AccuCinch ® Transcatheter Left Ventricular Restoration System, an investigational device currently being studied in the CORCINCH-HF pivotal trial. Ancora Heart is a privately held company located in Santa Clara, Calif. For more information, about Ancora Heart and its products, visit and follow the company on Facebook, LinkedIn and X. * Dr. Reisman reports travel support from Ancora Heart. 1 Martin SS, Aday AW, Almarzooq ZI, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee; Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347–913. 2 Murphy S, Ibrahim N, Januzzi J. Heart Failure with Reduced Ejection Fraction, A Review. JAMA. 2020;324(5):488-504 3 Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-596.
Business Wire
2 hours ago
- Business Wire
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the following link: The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at An archived webcast will be available on the company's website following the event. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099). The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects. The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo. Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject). There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm. 'We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.' said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. 'These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026.' About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward-Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding Forte's beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, the expected timeline for the Phase 2 celiac study and related readout, and the expected timing of topline results for the FB102 vitiligo study. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte's ability to obtain sufficient additional capital to continue to advance Forte's product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte's product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that results from preclinical and the Phase 1b trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte's business and operating results is contained in Forte's Quarterly Report on Forms 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.
